查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974300

兽用抗生素市场：按类别、动物类型、最终用户和治疗领域划分－全球预测，2026-2032年

Veterinary Antibiotics Market by Class, Animal Type, End-User, Therapeutic Areas - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，兽用抗生素市场价值将达到 53.2 亿美元，到 2026 年将成长至 55.9 亿美元，到 2032 年将达到 78.8 亿美元，复合年增长率为 5.76%。

主要市场统计数据
基准年 2025 53.2亿美元
预计年份：2026年 55.9亿美元
预测年份：2032年 78.8亿美元
复合年增长率 (%) 5.76%

兽医抗生素趋势的背景框架，强调临床方面、监管方面、供应链和合理使用抗生素的交汇点塑造了当今的治疗环境。

兽用抗生素领域在动物健康、食品安全和合理使用抗菌药物方面发挥着至关重要的作用。临床趋势、不断演变的法规结构以及公共卫生部门日益严格的监管正在重塑伴侣动物和家畜抗生素的选择、使用和监测方式。临床医生和生产者都面临着相互衝突的压力：既要保持疗效，又要控製药物残留和抗药性，还要在不断变化的生物安全要求下确保家畜健康。

该评估评估了美国在 2025 年实施的关税调整对各相关人员在供应链区域化、库存策略改变和待遇选择转变方面所发挥的催化作用。

美国2025年生效的关税政策变化对兽用抗生素供应链产生了多方面的影响，波及生产商、经销商和终端用户。部分进口商品关税的提高迫使企业重新思考筹资策略，加速投资本地产能，转向关税区外的替代供应商。虽然这种筹资策略的转变增强了部分相关人员的策略韧性，但也迫使其他利害关係人承担过渡成本，并重新认证相关人员以符合兽药品质标准。

为了促进策略优先排序和管理政策的製定，透过综合細項分析，整合药物类别、动物类型、最终用户管道和治疗适应症，可以获得深刻见解。

細項分析揭示了影响临床实践和商业性重点的关键治疗领域、类型和最终用户差异。

关于对美洲、欧洲、中东和非洲以及亚太地区区域策略的影响，我们将重点放在影响抗生素使用的监管、生产和控制方面的差异。

区域趋势持续对全球兽用抗生素的供应、监管和临床实践产生决定性影响。在美洲，监管力度加大和消费者期望的提高推动了更透明的合理用药报告和诊断技术的应用。同时，供应链正朝着本地化方向发展，以减少对长途进口的依赖。在欧洲、中东和非洲，法规环境日益多元化，欧洲部分地区实施了严格的使用限制和监测计划，而中东和非洲则优先考虑获取途径、能力建设和基础设施发展，以支持合理使用抗生素。在亚太地区，生产能力和製造技术正在快速发展，但各国监管成熟度的差异正在影响出口模式和本地供应。

主要参与企业之间的竞争定位和营运模式表明，投资组合重点、区域伙伴关係和管理一致性决定了其在行业内的影响力。

主要企业的趋势揭示了领导力、产品系列广度和策略投资如何塑造其在兽用抗生素领域的竞争地位。成熟的动物用药品公司持续利用其整合的研发能力、广泛的产品註册和完善的分销网络，以维持其在伴侣动物和家畜领域的市场地位。它们的策略重点通常是对给药系统和诊断技术的选择性投资，以增强治疗效果和用药依从性，同时在现有药物的生命週期管理与渐进式创新之间取得平衡。

为领导者提供可操作的优先建议，重点在于供应链韧性、综合管理解决方案和产品组合优化，以应对监管和临床挑战。

产业领导者应采取的实际步骤可归纳为三个相互依存的优先事项：增强供应链韧性、透过诊断技术和教育促进资源管理，以及优化产品和组合策略以反映临床实际情况和监管要求。增强供应链韧性需要采取策略性方法，实现供应商多元化，投资区域性製造地或合格的伙伴关係，并加强库存管理方法，以确保医疗保健服务的连续性，同时降低贸易中断带来的风险。

我们采用了高度透明的混合调查方法，结合了初步访谈、文献整合、监管审查、检验和情境分析，以支持我们的研究结果。

本调查方法结合了定性和定量技术，以确保研究的透明度和可重复性，同时产生可靠的实践见解。初步调查包括对兽医、法规专家、生产设施经理和分销主管进行结构化访谈，以收集他们对製剂行为、采购挑战和法规遵从性的直接意见。为了补充这些访谈，我们也进行了同侪审查文献回顾，并系统地检验了法规指导文件、产品标籤和药物监测记录，以确保临床和法规资讯的准确性。

整合策略洞察：透过协作管理、供应链韧性和务实的临床协调来维持兽用抗生素的有效性

总之，兽用抗生素生态系统正走在一条由监管调整、供应链重组以及对药物管理和诊断日益重视相关人员驱动的转型之路上。积极主动进行调整的利害关係人——例如投资于具有韧性的供应链、透过诊断技术开展合作以推动药物配方研发，以及调整产品策略以适应当地实际情况和治疗需求——将更有能力应对监管审查和不断变化的临床预期。这些调整的累积效应将建构一个更课责、数据驱动的治疗环境，在优先考虑动物健康结果的同时，保护公众健康利益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 兽用抗生素市场：依类别划分

  • Aminoglycosides
    • Amikacin
    • 阿普拉霉素
    • 庆大霉素
    • 卡那霉素
    • 新霉素
  • 氨苯醇
    • 阿齐达姆苯酚
    • 兰姆酒
    • 氟苯尼考
    • 甲硫霉素
    • 噻吩酚
  • 头孢菌素
    • 头孢氨芐
    • 头状花序
    • Cefazolin
    • 头孢维星
    • 塞夫蒂奥弗鲁
    • 头孢曲松
  • Fluoroquinolones
    • 达诺沙星
    • 地氟沙星
    • 恩诺沙星
    • 诺氟沙星
    • 奥比沙星
  • 大环内酯类
    • 阿奇霉素
    • 克拉霉素
    • 红霉素
    • 加米曲霉素
    • 螺旋霉素
    • 奇尔米考辛
    • 图拉霉素
    • 泰乐菌素
  • 其他奎诺酮抗生素
    • 辛诺沙星
    • 萘利酸
    • 奥索利酸
    • 哌咪酸
    • 罗沙沙星
  • 青霉素类
    • 阿莫西林
    • Ampicillin
    • 氯唑西林
    • 苯唑西林
    • 青霉素G
    • 青霉素V
  • 多粘菌素
    • 粘菌素/多粘菌素E
    • 多粘菌素B
  • 磺胺类药物
    • 磺胺嘧啶
    • 磺胺嘧啶
    • 磺胺甲噻唑
    • 磺胺甲噁唑
    • 柳氮磺胺吡啶
  • 四环霉素
    • 四环霉素
    • 多西环素
    • 四环霉素
    • 四环霉素
  • 甲氧芐啶系统
    • 复方磺胺甲组合药物
    • 甲氧芐啶磺胺嘧啶
    • 甲氧芐啶磺胺
    • 甲氧芐啶磺胺多辛
    • 复方磺胺甲噁唑（TMP-SMX）

第九章 兽用抗生素市场：依动物类型划分

  • 伴侣动物
    • 猫
    • 狗
  • 农场动物
    • 牛
    • 家禽
    • 绵羊/山羊
    • 猪

第十章 兽用抗生素市场：依最终用户划分

  • 畜牧设施
  • 家庭中的宠物主人
  • 动物医院

第十一章 兽用抗生素市场：依治疗领域划分

  • 皮肤感染疾病
  • 胃肠道感染疾病
  • 生殖系统感染疾病
  • 呼吸道感染疾病
  • 软组织与伤口感染疾病
  • 全身性行为感染
  • 尿道感染

第十二章 兽用抗生素市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 兽用抗生素市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 兽用抗生素市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国兽用抗生素市场

第十六章：中国兽用抗生素市场

第十七章：巴基斯坦兽用抗生素市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Ashish Life Science Private Limited
  • Bimeda Inc.
  • Biogenesis Bago SA
  • CH Boehringer Sohn AG & Co. KG
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Intas Pharmaceuticals Ltd.
  • Krka, dd, Novo mesto
  • Kyoritsuseiyaku Corporation
  • LABORATORIO AVI-MEX
  • LABORATORIOS CALIER, SA
  • Merck KGaA
  • Neogen Corporation
  • Ourofino Group
  • Sequent Scientific Ltd.
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-1B650A78937F

The Veterinary Antibiotics Market was valued at USD 5.32 billion in 2025 and is projected to grow to USD 5.59 billion in 2026, with a CAGR of 5.76%, reaching USD 7.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.32 billion
Estimated Year [2026] USD 5.59 billion
Forecast Year [2032] USD 7.88 billion
CAGR (%) 5.76%

Contextual framing of veterinary antibiotic dynamics highlighting clinical, regulatory, supply chain, and stewardship intersections shaping today's therapeutic landscape

The veterinary antibiotics landscape occupies a pivotal role at the intersection of animal health, food safety, and antimicrobial stewardship. Trends in clinical practice, evolving regulatory frameworks, and heightened scrutiny from public health authorities have collectively reshaped how antibiotics are selected, administered, and monitored across companion animals and livestock. Clinicians and producers alike are navigating competing pressures: the need to preserve therapeutic efficacy, the imperative to limit residues and resistance, and the operational demands of maintaining herd and flock health under changing biosecurity expectations.

In parallel, advances in pharmacology, diagnostics, and drug delivery are altering the therapeutic toolbox available to veterinarians. Rapid diagnostic tests and point-of-care tools are increasingly informing treatment decisions, enabling targeted therapy and shorter treatment courses when appropriate. Moreover, supply chain resiliency has become a strategic consideration as manufacturers, distributors, and end-users adapt to disruptions and implement redundancies that prioritize continuity of care.

This introduction situates the reader within a dynamic ecosystem in which clinical best practices, regulatory enforcement, and commercial strategies converge. It underscores the necessity for stakeholders to make evidence-based decisions that prioritize both animal welfare and public health, and it sets the stage for examining the consequential shifts, segmentation nuances, regional distinctions, and actionable steps that follow in the report.

The veterinary antibiotics sector has been transformed by several concurrent forces that are reconfiguring clinical paradigms, supply relationships, and regulatory oversight. Regulatory changes and heightened enforcement have driven tighter controls on use patterns, prompting both manufacturers and clinicians to rethink label indications, withdrawal periods, and off-label practices. These regulatory pressures have accelerated innovation in diagnostic tools and stewardship programs that prioritize judicious antibiotic use while incentivizing alternative measures such as vaccination, biosecurity, and management improvements.

Supply chain and sourcing dynamics have undergone a strategic reorientation as companies seek greater resilience. Manufacturers diversified supplier bases and regionalized production to mitigate geopolitical and transportation risks, and distributors increasingly emphasize inventory visibility and cold-chain integrity. These operational adjustments have improved continuity of supply for critical antibiotics but have also introduced complexity in procurement, compliance, and cost management. Concurrently, R&D priorities have shifted to focus not only on novel compounds but on formulations that facilitate targeted delivery, reduced dosing frequency, and minimized residue risk.

Market expectations have evolved alongside scientific and regulatory trends. End-users now demand greater transparency on antibiotic stewardship outcomes and traceability across product lifecycles. Veterinary practitioners are adopting evidence-driven prescribing supported by rapid diagnostics and enhanced data capture, which together enable outcome-based decisions and better antimicrobial usage monitoring. Collectively, these transformative shifts are producing a more accountable, data-rich, and strategically oriented antibiotics ecosystem in veterinary medicine.

Assessment of how 2025 United States tariff adjustments functioned as a catalyst for supply chain localization, inventory strategy changes, and therapeutic selection shifts across stakeholders

United States tariff policy changes that became noticeable in 2025 exert a multifaceted influence on the veterinary antibiotics supply chain, with effects that ripple across manufacturers, distributors, and end-users. Elevated tariffs on selected imports prompted firms to reassess sourcing strategies, accelerating investments in local production capabilities and alternative suppliers located outside tariff-impacted corridors. This sourcing pivot has improved strategic resilience for some stakeholders but has required others to absorb transition costs and requalify suppliers to meet veterinary pharmaceutical quality standards.

The tariff environment also accelerated the reconfiguration of trade routes and logistics practices. Importers and distributors responded by building longer lead times into procurement planning and by increasing reliance on regional warehouses to reduce exposure to tariff-related disruptions. In many cases, this led to a rebalancing of inventory practices toward higher safety stock for critical antibiotic families to prevent treatment interruptions. Veterinary service providers and producers responded by prioritizing antibiotics with stable supply profiles or by integrating non-antibiotic disease prevention approaches such as enhanced vaccination and improved husbandry practices.

Policy-driven cost pressures intensified conversations around product selection, formulary design, and stewardship prioritization. Given these dynamics, companies realigned commercial strategies to emphasize product portfolios that benefit from local manufacturing scalability, regulatory clarity, and traceability. Although tariffs were not the sole catalyst for change, they acted as a forcing function that accelerated decisions around supply chain localization, contract adjustments, and investment in alternative therapeutic and preventive measures across the veterinary ecosystem.

Comprehensive segmentation-driven insight synthesizing drug classes, animal types, end-user channels, and therapeutic indications to inform strategic prioritization and stewardship

Segmentation analysis reveals important therapeutic, species-specific, and end-user distinctions that shape clinical practice and commercial focus. The product class structure encompasses Aminoglycosides, Amphenicols, Cephalosporins, Fluoroquinolones, Macrolides, Other Quinolones, Penicillins, Polymixins, Sulfonamides, Tetracyclines, and Trimethoprim, with subcategories that include drugs such as Amikacin, Apramycin, Gentamicin, Kanamycin, Neomycin, Azidamfenicol, Chloramphenicol, Florfenicol, Metiamycin, Thiamphenicol, Cefalexin, Cefalonium, Cefazolin, Cefovecin, Ceftiofur, Ceftriaxone, Ciprofloxacin, Danofloxacin, Difloxacin, Enrofloxacin, Norfloxacin, Orbifloxacin, Azithromycin, Clarithromycin, Erythromycin, Gamithromycin, Spiramycin, Tilmicosin, Tulathromycin, Tylosin, Cinoxacin, Nalidixic Acid, Oxolinic Acid, Pipemidic Acid, Rosoxacin, Amoxicillin, Ampicillin, Cloxacillin, Oxacillin, Penicillin G, Penicillin V, Colistin/Polymyxin E, Polymyxin B, Sulfadiazine, Sulfamerazine, Sulfamethizole, Sulfamethoxazole, Sulfasalazine, Chlortetracycline, Doxycycline, Oxytetracycline, Tetracycline, and combinations involving Trimethoprim plus various sulfonamides including TMP-SMX.

Animal type delineation clarifies where demand and clinical practice diverge. Companion animals and livestock are examined with companion animals further characterized by cats and dogs, and livestock further divided into cattle, poultry, sheep and goats, and swine. End-user segmentation distinguishes animal production facilities, household pet owners, and veterinary clinics as primary channels through which antibiotics are accessed and administered, each with distinct procurement, storage, and stewardship practices. Therapeutic area segmentation highlights common intervention points including dermatological infections, gastrointestinal infections, reproductive system infections, respiratory infections, soft tissue and wound infections, systemic infections, and urinary tract infections, which together inform formulary development and prescribing protocols.

Understanding these segmentations in combination is crucial for aligning product development, distribution strategies, and stewardship initiatives. For example, certain classes such as macrolides and tetracyclines are often prioritized in respiratory and systemic indications in livestock, while specific cephalosporins and penicillins remain central to companion animal practice. Differences in end-user procurement behaviors, whether institutional purchasing at animal production facilities or retail and clinic-based access for pet owners, create distinct commercial pathways for manufacturers and distributors to navigate.

Regional strategy implications across Americas, Europe Middle East & Africa, and Asia-Pacific highlighting regulatory, production, and stewardship differentials affecting antibiotic usage

Regional dynamics continue to exert a determining influence on supply, regulation, and clinical practice in veterinary antibiotics across the globe. In the Americas, regulatory scrutiny and consumer expectations have driven more transparent stewardship reporting and increased adoption of diagnostics, while supply chains have leaned toward regionalization to reduce dependence on long-distance imports. Europe, Middle East & Africa present a heterogeneous regulatory tapestry, with parts of Europe enforcing stringent use restrictions and monitoring programs, and regions within the Middle East and Africa prioritizing access, capacity building, and infrastructure improvements to support appropriate antibiotic use. The Asia-Pacific region demonstrates rapid shifts in production capacity and manufacturing sophistication, combined with diverse regulatory maturity across countries that shapes export patterns and local availability.

These regional contrasts affect product lifecycle decisions and operational priorities. Companies evaluating formulation portfolios and registration investments must reconcile regional regulatory expectations with distribution channel realities. For instance, formulations that meet residue and withdrawal expectations in one jurisdiction may require additional studies or different labeling to comply elsewhere. Moreover, regional disease profiles and livestock production systems influence antibiotic selection; production systems in certain regions favor particular classes or administration routes due to management practices, climatic conditions, and prevailing pathogens.

Strategic actors therefore allocate resources based on regional priorities: investing in local manufacturing where supply security is a business imperative, enhancing regulatory affairs capabilities to navigate complex approvals, and tailoring stewardship communications to resonate with regional veterinary and producer communities. These region-specific strategies support both short-term operational continuity and long-term market access objectives.

Competitive positioning and operational patterns among leading players showing how portfolio focus, regional partnerships, and stewardship alignment determine industry influence

Key company dynamics reveal how leadership, portfolio breadth, and strategic investments shape competitive positioning within the veterinary antibiotics domain. Established animal health companies continue to leverage integrated research and development capabilities, broad product registries, and expansive distribution networks to sustain presence across both companion animal and livestock segments. Their strategic focus often balances incremental innovation with lifecycle management of legacy molecules, while investing selectively in delivery systems and diagnostics that enhance therapeutic outcomes and stewardship compliance.

Mid-sized and specialty players focus on niche therapeutic classes, regionally optimized formulations, or service-led models that pair products with diagnostic and advisory services. These firms frequently adopt agile commercialization approaches, pursuing targeted regulatory filings and partnerships to expand geographic reach without replicating the capital intensity of global manufacturing. Contract manufacturing organizations and regional distributors play an outsized role in ensuring product availability, enabling manufacturers to scale presence through strategic alliances.

Across the competitive landscape, successful companies demonstrate an ability to align stewardship messaging with commercial objectives, invest in supply chain transparency, and collaborate with veterinary associations, producers, and regulators to support responsible use. This alignment not only mitigates regulatory and reputational risk but also fosters trust with clinicians and producers who increasingly evaluate suppliers based on quality, traceability, and ethical practices.

Actionable priority recommendations for leaders focusing on supply resilience, integrated stewardship solutions, and portfolio optimization to navigate regulatory and clinical challenges

Actionable steps for industry leaders coalesce around three interdependent priorities: strengthening supply resilience, advancing stewardship through diagnostics and education, and optimizing product and portfolio strategies to reflect clinical realities and regulatory expectations. Strengthening supply resilience requires a strategic approach to supplier diversification, investment in regional manufacturing or qualified partnerships, and enhanced inventory management practices that reduce vulnerability to trade disruptions while ensuring continuity of care.

Advancing stewardship entails integrating rapid diagnostics, data capture, and clinician education into commercial offerings so that prescribing decisions are supported by timely information and outcome monitoring. Companies should proactively partner with veterinary associations, producers, and policy makers to design stewardship frameworks that balance access with preservation of antibiotic efficacy. This collaborative approach reinforces trust and positions firms as constructive participants in public health objectives.

Optimizing product and portfolio strategies means prioritizing formulations and indications that align with regional disease burdens, withdrawal requirements, and end-user workflows. Manufacturers should consider flexible regulatory pathways and modular registration strategies to accelerate access across jurisdictions. Additionally, embedding service elements-such as diagnostic support, training modules, and tailored stewardship materials-creates differentiation and supports sustainable demand for products within evolving clinical and regulatory environments.

Transparent, mixed-methods research approach blending primary interviews, literature synthesis, regulatory review, triangulation, and scenario analysis to underpin findings

The research methodology combines qualitative and quantitative techniques designed to produce robust, actionable insights while ensuring transparency and repeatability. Primary research included structured interviews with veterinarians, regulatory experts, production facility managers, and distribution executives to capture first-hand perspectives on prescribing behavior, procurement challenges, and regulatory compliance. These interviews were complemented by peer-reviewed literature reviews and a systematic examination of regulatory guidance documents, product labeling, and pharmacovigilance records to ensure clinical and regulatory accuracy.

Secondary research incorporated publicly available technical papers, clinical guidelines, and industry white papers to contextualize primary findings within broader scientific and policy trends. Data triangulation methods were employed to reconcile differing viewpoints and validate thematic conclusions, ensuring that strategic recommendations rest on convergent evidence. The approach also included scenario analysis to explore operational implications of policy shifts and supply chain disruptions, and sensitivity checks to test the robustness of qualitative inferences under alternative assumptions.

Ethical considerations and data governance protocols were observed throughout, ensuring interviewee confidentiality and adherence to relevant data protection norms. The methodology is transparent about its limitations, acknowledging areas where evidence is emerging and where further targeted research or clinical studies could strengthen causal understanding.

Synthesis of strategic implications highlighting collaborative stewardship, supply chain resilience, and pragmatic clinical alignment to sustain veterinary antibiotic efficacy

In conclusion, the veterinary antibiotics ecosystem is in the midst of purposeful change driven by regulatory realignment, supply chain recalibration, and a growing emphasis on stewardship and diagnostics. Stakeholders who proactively adapt-by investing in resilient supply chains, partnering to advance diagnostic-driven prescribing, and aligning product strategies with regional and therapeutic realities-are positioned to navigate both regulatory scrutiny and shifting clinical expectations. The cumulative effect of these adjustments is a more accountable and data-informed therapeutic environment that prioritizes animal health outcomes while safeguarding public health interests.

While challenges remain, particularly around harmonizing regulations across regions and ensuring equitable access to quality antibiotics, the path forward is defined by collaboration among manufacturers, clinicians, regulators, and producers. Shared commitments to transparency, evidence-driven prescribing, and investment in alternatives to routine antibiotic use will shape the sector's sustainability. The insights presented here are intended to inform strategy, guide tactical decisions, and stimulate constructive dialogue toward responsible antibiotic stewardship across the veterinary continuum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Antibiotics Market, by Class

  • 8.1. Aminoglycosides
    • 8.1.1. Amikacin
    • 8.1.2. Apramycin
    • 8.1.3. Gentamicin
    • 8.1.4. Kanamycin
    • 8.1.5. Neomycin
  • 8.2. Amphenicols
    • 8.2.1. Azidamfenicol
    • 8.2.2. Chloramphenicol
    • 8.2.3. Florfenicol
    • 8.2.4. Metiamycin
    • 8.2.5. Thiamphenicol
  • 8.3. Cephalosporins
    • 8.3.1. Cefalexin
    • 8.3.2. Cefalonium
    • 8.3.3. Cefazolin
    • 8.3.4. Cefovecin
    • 8.3.5. Ceftiofur
    • 8.3.6. Ceftriaxone
  • 8.4. Fluoroquinolones
    • 8.4.1. Danofloxacin
    • 8.4.2. Difloxacin
    • 8.4.3. Enrofloxacin
    • 8.4.4. Norfloxacin
    • 8.4.5. Orbifloxacin
  • 8.5. Macrolides
    • 8.5.1. Azithromycin
    • 8.5.2. Clarithromycin
    • 8.5.3. Erythromycin
    • 8.5.4. Gamithromycin
    • 8.5.5. Spiramycin
    • 8.5.6. Tilmicosin
    • 8.5.7. Tulathromycin
    • 8.5.8. Tylosin
  • 8.6. Other Quinolones
    • 8.6.1. Cinoxacin
    • 8.6.2. Nalidixic Acid
    • 8.6.3. Oxolinic Acid
    • 8.6.4. Pipemidic Acid
    • 8.6.5. Rosoxacin
  • 8.7. Penicillins
    • 8.7.1. Amoxicillin
    • 8.7.2. Ampicillin
    • 8.7.3. Cloxacillin
    • 8.7.4. Oxacillin
    • 8.7.5. Penicillin G
    • 8.7.6. Penicillin V
  • 8.8. Polymixins
    • 8.8.1. Colistin/Polymyxin E
    • 8.8.2. Polymyxin B
  • 8.9. Sulfonamides
    • 8.9.1. Sulfadiazine
    • 8.9.2. Sulfamerazine
    • 8.9.3. Sulfamethizole
    • 8.9.4. Sulfamethoxazole
    • 8.9.5. Sulfasalazine
  • 8.10. Tetracyclines
    • 8.10.1. Chlortetracycline
    • 8.10.2. Doxycycline
    • 8.10.3. Oxytetracycline
    • 8.10.4. Tetracycline
  • 8.11. Trimethoprim
    • 8.11.1. Trimethoprim Plus Sulfamethazine
    • 8.11.2. Trimethoprim-Sulfadiazine
    • 8.11.3. Trimethoprim-Sulfadimidine
    • 8.11.4. Trimethoprim-Sulfadoxine
    • 8.11.5. Trimethoprim-Sulfamethoxazole (TMP-SMX)

9. Veterinary Antibiotics Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Livestock
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep & Goats
    • 9.2.4. Swine

10. Veterinary Antibiotics Market, by End-User

  • 10.1. Animal Production Facilities
  • 10.2. Household Pet Owners
  • 10.3. Veterinary Clinics

11. Veterinary Antibiotics Market, by Therapeutic Areas

  • 11.1. Dermatological Infections
  • 11.2. Gastrointestinal Infections
  • 11.3. Reproductive System Infections
  • 11.4. Respiratory Infections
  • 11.5. Soft Tissue & Wound Infections
  • 11.6. Systemic Infections
  • 11.7. Urinary Tract Infections

12. Veterinary Antibiotics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Veterinary Antibiotics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Veterinary Antibiotics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Veterinary Antibiotics Market

16. China Veterinary Antibiotics Market

17. Pakistan Veterinary Antibiotics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Ashish Life Science Private Limited
  • 18.6. Bimeda Inc.
  • 18.7. Biogenesis Bago S.A.
  • 18.8. C.H. Boehringer Sohn AG & Co. KG
  • 18.9. Ceva Sante Animale
  • 18.10. Dechra Pharmaceuticals PLC
  • 18.11. Eco Animal Health Group PLC
  • 18.12. Elanco Animal Health Incorporated
  • 18.13. Intas Pharmaceuticals Ltd.
  • 18.14. Krka, d. d., Novo mesto
  • 18.15. Kyoritsuseiyaku Corporation
  • 18.16. LABORATORIO AVI-MEX
  • 18.17. LABORATORIOS CALIER, S.A.
  • 18.18. Merck KGaA
  • 18.19. Neogen Corporation
  • 18.20. Ourofino Group
  • 18.21. Sequent Scientific Ltd.
  • 18.22. Vetoquinol SA
  • 18.23. Virbac SA
  • 18.24. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. PAKISTAN VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMIKACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMIKACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY APRAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY APRAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY APRAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY KANAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY KANAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY KANAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NEOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NEOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZIDAMFENICOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZIDAMFENICOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZIDAMFENICOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORAMPHENICOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORAMPHENICOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORAMPHENICOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLORFENICOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLORFENICOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLORFENICOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY METIAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY METIAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY METIAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THIAMPHENICOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THIAMPHENICOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THIAMPHENICOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALEXIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALONIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALONIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFALONIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFAZOLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFAZOLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFAZOLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFOVECIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFOVECIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFOVECIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTIOFUR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTIOFUR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTIOFUR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DANOFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DANOFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DANOFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DIFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DIFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DIFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ENROFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ENROFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NORFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NORFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NORFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ORBIFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ORBIFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ORBIFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLARITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLARITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLARITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GAMITHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GAMITHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GAMITHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SPIRAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SPIRAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TULATHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TULATHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CINOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CINOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CINOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NALIDIXIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NALIDIXIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY NALIDIXIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXOLINIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXOLINIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXOLINIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PIPEMIDIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PIPEMIDIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PIPEMIDIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ROSOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ROSOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ROSOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMOXICILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPICILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLOXACILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CLOXACILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXACILLIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXACILLIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXACILLIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLIN V, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COLISTIN/POLYMYXIN E, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COLISTIN/POLYMYXIN E, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COLISTIN/POLYMYXIN E, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMYXIN B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFADIAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFADIAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFADIAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMERAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMERAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMERAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHIZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHIZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHIZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHOXAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHOXAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFAMETHOXAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORTETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CHLORTETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXYTETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY OXYTETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM PLUS SULFAMETHAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM PLUS SULFAMETHAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM PLUS SULFAMETHAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIMIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIMIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADIMIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADOXINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADOXINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFADOXINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL PRODUCTION FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL PRODUCTION FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL PRODUCTION FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY HOUSEHOLD PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY HOUSEHOLD PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY HOUSEHOLD PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DERMATOLOGICAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DERMATOLOGICAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY DERMATOLOGICAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REPRODUCTIVE SYSTEM INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REPRODUCTIVE SYSTEM INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REPRODUCTIVE SYSTEM INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SOFT TISSUE & WOUND INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SOFT TISSUE & WOUND INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SOFT TISSUE & WOUND INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SYSTEMIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SYSTEMIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY SYSTEMIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 275. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 276. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 278. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2032 (USD MILLION)
  • TABLE 279. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 280. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 281. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 282. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 283. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 284. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2032 (USD MILLION)
  • TABLE 285. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 286. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 287. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2032 (USD MILLION)
  • TABLE 288. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 290. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 291. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 292. AMERICAS VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY AMPHENICOLS, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY OTHER QUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 302. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY POLYMIXINS, 2018-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 304. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY TRIMETHOPRIM, 2018-2032 (USD MILLION)
  • TABLE 306. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 308. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 310. NORTH AMERICA VETERINARY ANTIBIOTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (US